Tectonic Therapeutic, Inc.
$28.97
+5.6%Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -7.2).
Valuation inputs: P/E -7.2, earnings yield N/A, momentum +5.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -29.5%, ROIC -33.3%).
Profitability stack: net margin 0.0%, ROE -29.5%, ROIC -33.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +3.7%, momentum +5.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Tectonic Therapeutic, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Tectonic Therapeutic, Inc. Fair Value Envelope
No Revenue Data
TECX has not reported any revenue values in the available annual periods.
Tectonic Therapeutic, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
TECX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
TECX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
TECX has not reported any net profit margin values in the available annual periods.
Tectonic Therapeutic, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tectonic Therapeutic, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tectonic Therapeutic, Inc. Street Expectations Map
Wall Street analysts project that TECX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 72.00, with estimates ranging from a low of 60.00 to a high of 81.00.
The consensus 1-year price target stands at 72.00, with estimates ranging from a low of 60.00 to a high of 81.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Tectonic Therapeutic, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.40M and sold $639K worth of TECX shares, resulting in $1.76M of net buying activity.
3 Months
0
0.00
18.1K
544.41K
-544K
-$544K
3-6 Months
11.0K
235.16K
3.3K
77.63K
+158K
+$158K
6-9 Months
62.2K
915.40K
0
0.00
+915K
+$915K
9-12 Months
51.0K
1.25M
859
17.02K
+1.2M
+$1.23M
Top Buyers
Reicin Alise
Director, Officer: Chief Executive Officer
$498K
Lochner Daniel
Officer: Chief Financial Officer
$275K
Tipirneni Praveen P.
Director
$250K
Springer Timothy A
Director, 10 Percent Owner:
$250K
Donenberg Phillip B.
Director
$250K
Top Sellers
Ruddy Marcella K.
Officer: Chief Medical Officer
$363K
Mcnamara Peter
Officer: Chief Scientific Officer
$259K
Reicin Alise
Director, Officer: Chief Executive Officer
$17K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.76M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
TECX has not reported any dividend yield values in the available annual periods.
tecx Dividend History
Learning Layer
Related Guides
Build conviction on TECX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.